Hatch Waxman > Nova Content
Federal Circuit Summaries
Before Reyna, Bryson, and Stoll. Appeal from the Patent Trial and Appeal Board.
Summary: A petitioner in an Inter Partes Review may... Read More »
Federal Circuit Summary
Before Wallach, O’Malley, and Schall. Appeal from the Patent Trial and Appeal Board.
Summary: PGR petitioner has standing... Read More »
Federal Circuit Summary
Before Moore, Mayer, and Stoll. Appeal from the United States District Court for the District of New Jersey.
Summary: Plain... Read More »
Federal Circuit Summary
Before Prost, Lourie and Hughes. Appeal from the United States District Court for the District of Delaware.
Summary: When... Read More »
Lundbeck Pharmaceutical Company, headquartered in Denmark, recently announced the acquisition of Prexton Therapeutics B.V. for $1.1 billion (U.S.)(1). Lundbeck... Read More »
Xeris Pharmaceuticals, Inc. (“Xeris”) recently announced successful completion of both adult and pediatric clinical studies for its glucagon rescue pen... Read More »
The PTAB dismissed the Saint Regis Mohawk Tribe’s attempt to avoid IPR of patents covering Restasis®, which Allergan transferred to the Tribe in a highly... Read More »
As an introduction to this topic, please reread my post of July 5, 2017 about The Cleveland Clinic v. True Health Diagnostics, subtitled “Time to Redefine... Read More »
Federal Circuit Summary
In Medicines Co. v. Hospira, Inc., 2014-1469; 2014-1504 (Dyk, Wallach, Hughes), the Federal Circuit affirmed the district court’s... Read More »
Federal Circuit Summary
Before Taranto, Clevenger, and Stoll. Appeal from the United States District Court for the District of Delaware.
Summary: Proceeding... Read More »
Written by Daniel A. Kamkar and Michael L. Fuller
On October 9, 2017, California Governor Jerry Brown signed the new drug price transparency bill SB 17.[1] ... Read More »
Written by Robert J. Hilton, Ph.D. and Jing Liu, Ph.D.
On September 14, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Aliqopa... Read More »
Written by Peter Law and Kerry S. Taylor, Ph.D.
In a creative move to take advantage of recent PTAB decisions regarding Sovereign Immunity, (see e.g., Covidien LP ... Read More »
Written by Scott Siera, Ph.D. and Eric Furman, Ph.D.
Seven years after Mylotarg® (gemtuzumab ozogamicin) was voluntarily withdrawn from the market, the U.S... Read More »
Written by Daniel K. Yarbrough, Ph.D. and Brenden S. Gingrich, Ph.D.
On August 1, 2017, the U.S. Food and Drug Administration released its draft guidance titled... Read More »
Written by Casey D. Donahoe, Ph.D. and Kerry S. Taylor, Ph.D.
Hospira (owned by Pfizer) filed five IPR petitions against Genentech patents that Genentech asserted ... Read More »
Written by Jane Xia and Jing Liu, Ph.D.
MILLENNIUM PHARMACEUTICALS, INC. v. SANDOZ INC
(Fed. Cir. July 17, 2017) (NEWMAN, Mayer, O’Malley)
This case ... Read More »
Written by Mark Speegle and Sean Murray
Edited by John Sganga, Joseph Cianfrani, and Boris Zelkind
On July 14, 2017, in a stunning reversal of fortune, a... Read More »
Written by Stephanie M. Johnson and Paul Stewart
Edited by John Sganga, Joseph Cianfrani, and Boris Zelkind
On July 18, 2017, after two years of litigation... Read More »
In Regeneron Pharmaceuticals v. Merus N.V., Appeal No. 2016-1346 (Fed. Cir., July 27, 2017), a split three-judge panel of Prost, Wallach and Newman (Newman... Read More »